Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-03-13

CGMP Deviations

Dr. Reddy's Laboratories, Inc.

US Class I Ongoing · initiated 2025-03-13

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap p…

Alchemee, LLC

US Class II Ongoing · initiated 2025-03-12

Chemical contamination: Presence of benzene

Alchemee, LLC

US Class II Ongoing · initiated 2025-03-12

Chemical contamination: Presence of benzene

KABANA SKIN CARE

US Class II Ongoing · initiated 2025-03-12

cGMP deviations

KABANA SKIN CARE

US Class II Ongoing · initiated 2025-03-12

cGMP deviations

KABANA SKIN CARE

US Class II Ongoing · initiated 2025-03-12

cGMP deviations

KABANA SKIN CARE

US Class II Ongoing · initiated 2025-03-12

cGMP deviations

Fruit Of The Earth, Inc.

US Class II Ongoing · initiated 2025-03-11

Chemical contamination: presence of benzene

FDC Limited

US Class II Ongoing · initiated 2025-03-11

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Fruit Of The Earth, Inc.

US Class II Ongoing · initiated 2025-03-11

Chemical contamination: presence of benzene

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-03-11

CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.

Jamp Calcium Carbonate 500 + Vitamin D 1000 Tablet

Canada Type III Ongoing · initiated 2025-03-11

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2025-03-07

Super-Potent Drug: Out of specification potency results were obtained.

Slate Run Pharmaceuticals

US Class II Completed · initiated 2025-03-07

CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2025-03-07

Super-Potent Drug: Out of specification potency results were obtained.

Slate Run Pharmaceuticals

US Class II Completed · initiated 2025-03-07

CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.

Consumer Product Partners, LLC

US Class II Ongoing · initiated 2025-03-07

Labeling; Label Mixup; some bottles have an incorrect back label indicating 91% Isopropyl Alcohol

Exela Pharma Sciences LLC

US Class II Ongoing · initiated 2025-03-07

Lack of Assurance of Sterility

ASEGUA THERAPEUTICS LLC

US Class II Ongoing · initiated 2025-03-07

Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton.

Direct Rx

US Class II Ongoing · initiated 2025-03-07

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Direct Rx

US Class II Ongoing · initiated 2025-03-07

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

QuVa Pharma, Inc.

US Class II Ongoing · initiated 2025-03-06

Lack of Assurance of Sterility

QuVa Pharma, Inc.

US Class II Ongoing · initiated 2025-03-06

Lack of Assurance of Sterility

QuVa Pharma, Inc.

US Class II Ongoing · initiated 2025-03-06

Lack of Assurance of Sterility